Skip to main content

Table 1 Patient characteristics and treatment response

From: Treating C3 glomerulopathy with eculizumab

 

C3GN1

C3GN2

C3GN3

DDD1

C3GN4

DDD2

C3GN5

native/grafta

graft

native

graft

native

graft

native

native

Baseline SCr (mg/dl)

1.9

2.3

2.1

1.5

3.3

2.1

0.8

Baseline UPCR (g/g)

5.4

0.3

0.3

5.0

3.4

5.4

5.6

Baseline hematuriab (0–4)

4

4

3

4

4

4

2

Therapy

pre Tx

none

none

pre Tx

prednisone, MMF, azathioprine

none

pre Tx

cyclo-

sporine A, cyclophos-phamide

none

PEX, FFP, immune-globulins, prednisone, MMF [25]

post Tx

prednisone, tacrolimus, MMF, rituximab

 

post Tx

prednisone, tacrolimus, MMF (graft)

 

post Tx

prednisone, tacrolimus, MMF, cyclophos-phamide, PEX [41] (graft)

  

Time to graft relaps (months)

48

3

de novo C3GN 135 months post Tx

Time diagnosis to eculizumab (months)

144 (native); 0 (graft)

7

88 (native); 2 (graft)

128

2 (graft)

7

11

Treatment duration (months)

27

26

9

24

3; 3

16

28

Response SCr

stable

yes

stable

stable

initially yes; recurrence no

initially stable; ultimately no

no

Response UPCR

yes

stable

stable

initially yes; ultimately stable

initially yes; recurrence no

initially stable; ultimately no

no

Response hematuria

stable

yes

stable

yes

stable

yes

yes

  1. Abbreviations: FFP fresh frozen plasma, MMF mycophenolate mofetil, PEX plasmapheresis, Tx kidney transplantation
  2. anative: applies to native kidney; graft: applies to kidney transplant
  3. bhematuria measured by urine dipstic (scale from 0 to 4)